MarketCap
Facebook
X
Telegram
Country |
 Germany |
IPO year |
2017 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
67.3 M |
Market Cap[1] |
$ 81.4 M |
EBITDA (LTM) |
- |
P/E (LTM) |
-1.926471 |
P/S (LTM) |
3005.274317 |
EPS (LTM) |
-0.68 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
NextCure
NXTC
|
$ 5.97 | -4.78 % | $ 17 M | Nasdaq Global Select Market |  USA |
 |
Rocket Pharmaceuticals
RCKT
|
$ 2.46 | -2.96 % | $ 273 M | Nasdaq Global Select Market | USA |
 |
PMV Pharmaceuticals
PMVP
|
$ 1.22 | -2.8 % | $ 64.1 M | Nasdaq Global Select Market | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 7.29 | -1.02 % | $ 634 M | Nasdaq Global Select Market | USA |
 |
Kymera Therapeutics
KYMR
|
$ 136.45 | -1.74 % | $ 11.5 B | Nasdaq Global Market | USA |
 |
Oragenics
OGEN
|
$ 0.35 | -1.47 % | $ 755 K | NYSE American | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.8 | -1.75 % | $ 365 M | Nasdaq Global Select Market | USA |
 |
Passage Bio
PASG
|
$ 3.81 | 11.08 % | $ 12.2 M | Nasdaq Global Select Market | USA |
 |
Vaxcyte
PCVX
|
$ 66.44 | -1.61 % | $ 9.04 B | Nasdaq Global Select Market | USA |
 |
Relay Therapeutics
RLAY
|
$ 19.81 | -2.87 % | $ 3.4 B | Nasdaq Global Market | USA |
 |
Precigen
PGEN
|
$ 4.51 | -4.76 % | $ 1.41 B | Nasdaq Global Select Market | USA |
 |
Avidity Biosciences
RNA
|
$ 8.23 | -1.79 % | $ 1.13 B | Nasdaq Global Select Market | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.82 | -2.07 % | $ 4.91 M | Nasdaq Capital Market | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 337.69 | 1.42 % | $ 7.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.78 | 0.53 % | $ 291 M | Nasdaq Global Select Market | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.31 | -5.07 % | $ 138 M | Nasdaq Global Market |  Niderland |
 |
Ocular Therapeutix
OCUL
|
$ 6.62 | -3.36 % | $ 1.24 B | Nasdaq Global Select Market | USA |
 |
PolyPid Ltd.
PYPD
|
$ 6.3 | 0.96 % | $ 103 M | Nasdaq Global Select Market |  Israel |
 |
Outlook Therapeutics
OTLK
|
$ 0.46 | -0.84 % | $ 16 M | Nasdaq Global Select Market | USA |
 |
uniQure N.V.
QURE
|
$ 22.7 | -0.39 % | $ 1.31 B | Nasdaq Global Select Market | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 16.13 | -1.71 % | $ 1.59 B | Nasdaq Global Select Market,SPB | USA |
 |
Rafael Holdings
RFL
|
$ 1.11 | 2.45 % | $ 57 M | NYSE | USA |
 |
REGENXBIO
RGNX
|
$ 7.66 | -5.08 % | $ 395 M | Nasdaq Global Select Market,SPB | USA |
 |
Rigel Pharmaceuticals
RIGL
|
$ 43.83 | 4.22 % | $ 788 M | Nasdaq Global Select Market | USA |
 |
SELLAS Life Sciences Group
SLS
|
$ 8.38 | -2.39 % | $ 914 M | Nasdaq Capital Market | USA |
 |
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market | USA |
 |
Генетико
GECO
|
- | - | - | MOEX |  Russia |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Tenax Therapeutics
TENX
|
$ 1.69 | -5.34 % | $ 66.3 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market | Israel |
 |
Abcam plc
ABCM
|
- | - | $ 4.9 B | Nasdaq Global Select Market |  Britain |
 |
Rezolute
RZLT
|
$ 4.01 | 3.83 % | $ 417 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
$ 0.61 | -8.44 % | $ 65.1 M | Nasdaq Global Market | Britain |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | Germany |
 |
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Nasdaq Global Select Market,SPB | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
- | -1.58 % | $ 28.1 M | Nasdaq Global Market | China |
 |
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market |  Belgium |
 |
Seer
SEER
|
$ 1.62 | -3.57 % | $ 89.7 M | Nasdaq Global Select Market | USA |
 |
Gracell Biotechnologies
GRCL
|
- | - | $ 3.37 B | Nasdaq Global Select Market | China |
 |
Shattuck Labs
STTK
|
$ 4.86 | -2.71 % | $ 338 M | Nasdaq Global Select Market | USA |
|
Silence Therapeutics plc
SLN
|
$ 19.78 | 0.15 % | $ 2.8 B | Nasdaq Global Select Market | Britain |
 |
Stoke Therapeutics
STOK
|
$ 27.16 | -1.98 % | $ 1.61 B | Nasdaq Global Select Market,SPB | USA |
 |
Sutro Biopharma
STRO
|
$ 10.08 | -5.0 % | $ 85.7 M | Nasdaq Global Select Market | USA |
 |
Soligenix
SNGX
|
$ 0.32 | -6.35 % | $ 1.66 M | Nasdaq Capital Market | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
$ 42.54 | -1.0 % | $ 48.7 B | NYSE | Israel |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.